Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 25, 2026

'Raise Your Hand If You've Bought Or Sold Something With Bitcoin': Fed Official Reportedly Slams Crypto And Stablecoins As 'Utterly Useless'

View original at finance.yahoo.com
'Raise Your Hand If You've Bought Or Sold Something With Bitcoin': Fed Official Reportedly Slams Crypto And Stablecoins As 'Utterly Useless' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Stablecoins do not do anything that Venmo and PayPal do not already do

    80% confidence
  • When you ask basic questions about crypto or stablecoins there's just nothing there

    80% confidence
  • Cryptocurrencies are like Beanie Babies with no clear fundamentals beyond bypassing banking regulations

    80% confidence
  • Bitcoin is not digital gold or no longer digital gold

    80% confidence
  • Bitcoin is transitioning from being purely speculative to having a real use case

    80% confidence
  • Stablecoins are not useful in the U.S. and their cross-border benefits are lost when converted to native currencies

    80% confidence
  • Cryptocurrencies are utterly useless

    80% confidence
  • Bitcoin is not a means of payment or currency and is unlikely to replace gold or fiat

    80% confidence
  • Stablecoin proponents only provide buzzword salad answers about tokenized deposits without explaining real consumer benefits

    80% confidence
  • AI has real long-term potential for the U.S. economy as opposed to crypto

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com